T cell reactivity against antigen 85 in HIV-infection.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

T cell reactivity against antigen 85 in HIV-infection.

Abstr Gen Meet Am Soc Microbiol. 1994;94:190 (abstract no. U-100). Unique Identifier : AIDSLINE ASM94/94313076
Huygen K; Gerard M; Farber CM; Drowart A; van Vooren JP; Clumeck N; Pasteur Instituut van Brabant, Brussels, Belgium.

Abstract: Antigen 85 (30-32 kD) is the major secreted protein antigen from M. tuberculosis/bovis BCG culture filtrate. We have previously shown that 32 kD component (Ag85A) of this antigen demonstrates powerful T cell stimulatory properties resulting in T cell proliferation and IFN-gamma secretion by PBMC from all healthy tuberculin-positive volunteers and by only a minority of tuberculosis patients, suggesting a protective role of T cell immunity to Ag85 in tuberculous infection (1). Endogenous reactivation of latent M. tuberculosis, exogenous infection with the Koch bacillus and disease caused by mycobacteria other than M. tuberculosis (MOTT) form a serious health problem in HIV-infection. Predictive markers of increased risk for developing disease, other than CD4 counts, are not defined for the moment. The purpose of this study is to analyze T cell reactivity against Ag85 in tuberculin-negative (ID-) and tuberculin-positive (ID+) HIV-seropositive subjects (CDC stages II and III) and in AIDS patients (CDC IV C1 and IV C2). TABULAR DATA, SEE ABSTRACT VOLUME. *: number of individuals that demonstrated a positive in vitro T cell response to PPD or Ag85. In stage CDC IV C1, six patients suffered from MOTT and all were unresponsive to PPD and Ag85. One patient with extrapulmonary TB was reactive to PPD but not to Ag85. These results suggest that decreased T cell reactivity against Ag85 occurs early during HIV infection, even before decreases in PPD responsiveness can be measured. A follow-up study on the HIV+/ID+ cohort will indicate whether T cell reactivity against the antigen can be used as a predictive marker of mycobacterial complications.

Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Antigens, Bacterial/*IMMUNOLOGY AIDS-Related Opportunistic Infections/EPIDEMIOLOGY/IMMUNOLOGY Comparative Study CD4-Positive T-Lymphocytes/*IMMUNOLOGY Human HIV Seropositivity/*IMMUNOLOGY *Lymphocyte Transformation Mycobacterium bovis/*IMMUNOLOGY Predictive Value of Tests Risk Factors T-Lymphocytes/*IMMUNOLOGY Tuberculin Test Tuberculosis/*EPIDEMIOLOGY/MICROBIOLOGY ABSTRACT
941030
M94A0878

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .